Kalank Games Raises $1.7M in Funding

Shaarp

Grâce à Shaarp, optimisez votre prospection commerciale en transformant chaque interaction en succès et en gagnant du temps grâce à l'IA. Maîtrisez les informations en ligne les plus récentes sur vos prospects et clients et faites en des atouts pour toutes vos interactions. Shaarp connaît votre offre et vous aide à mieux comprendre vos interlocuteurs et leurs problématiques. Vous êtes l'intelligence.

Granit

Granit deploys AI agents that automate the administrative back-office of healthcare facilities, including eligibility checks, billing, claims processing, and payment reconciliation. Its agents work within existing software and portals, requiring no new systems, and are operational within 48 hours. The company is backed by Seedcamp and has raised €5M to accelerate growth.

DAMOCLES Diagnostics

DAMOCLES Diagnostics is a deeptech start-up founded in 2023 in Limoges. It develops an innovative technology that allows the measurement of the biophysical properties of a microorganism in a few minutes, without labeling and respecting the living. The first targeted application is the antibiotic sensitivity test (AST) which is very fast and automated. The innovation is based on the transformation of a proven technology in oncology, adapted to medical microbiology laboratories, both in human and animal health. The DAMAST system includes a machine, a diagnostic software and kits for a wide range of applications in microbiology. DAMOCLES Diagnostics has validated its DAMAST system on more than 500 bacteria/antibiotic combinations, with performances in accordance with CE-IVD regulations. A second internal clinical study is underway on another panel of bacterial species and antibiotics. Our team is composed of 8 people with transdisciplinary skills. We are supported by the INSERM U1092 RESINFIT and U1308 CAPTUR laboratories, which gives us privileged access to cutting-edge technical platforms. Having received many expressions of interest from future customers (private laboratories and hospitals), we aim for the industrialization of the DAMAST system in 2025, followed by the launch of a clinical trial in 2026.

Aíma

Aíma develops advanced liquid biopsy tests for minimal residual disease and early cancer detection. Our whole-genome methylation and fragmentomics platform combines AI with ultra-sensitive sequencing to detect cancer DNA and determine its tissue of origin. We collaborate with leading clinical centers to bring faster, more accurate and more accessible cancer diagnostics to patients.